NanoenTekInc (039860) - Total Liabilities

Latest as of September 2025: ₩5.42 Billion KRW ≈ $3.68 Million USD

Based on the latest financial reports, NanoenTekInc (039860) has total liabilities worth ₩5.42 Billion KRW (≈ $3.68 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

NanoenTekInc - Total Liabilities Trend (2007–2024)

This chart illustrates how NanoenTekInc's total liabilities have evolved over time, based on quarterly financial data. See NanoenTekInc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

NanoenTekInc Competitors by Total Liabilities

The table below lists competitors of NanoenTekInc ranked by their total liabilities.

Company Country Total Liabilities
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
USA $583.17K
Immunoprecise Antibodies Ltd
NASDAQ:IPA
USA $20.82 Million
Western Asset Investment Grade Defined Opportunity Closed Fund
NYSE:IGI
USA $927.80K
KB Star REIT Co. Ltd.
KO:432320
Korea ₩846.86 Billion
Strix Group Plc
F:SG9
Germany €131.53 Million
Aureus Greenway Holdings Inc.
NASDAQ:PUSA
USA $1.54 Million
Caturkarda Depo Bangunan PT Tbk
JK:DEPO
Indonesia Rp990.41 Billion
ReaLy Development & Construction
TWO:2596
Taiwan NT$3.86 Billion

Liability Composition Analysis (2007–2024)

This chart breaks down NanoenTekInc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is NanoenTekInc worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 13.31 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.07 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NanoenTekInc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NanoenTekInc (2007–2024)

The table below shows the annual total liabilities of NanoenTekInc from 2007 to 2024.

Year Total Liabilities Change
2024-12-31 ₩5.01 Billion
≈ $3.40 Million
+0.54%
2023-12-31 ₩4.99 Billion
≈ $3.38 Million
-11.42%
2022-12-31 ₩5.63 Billion
≈ $3.81 Million
-44.35%
2021-12-31 ₩10.11 Billion
≈ $6.85 Million
+38.01%
2020-12-31 ₩7.33 Billion
≈ $4.97 Million
+30.55%
2019-12-31 ₩5.61 Billion
≈ $3.80 Million
-19.93%
2018-12-31 ₩7.01 Billion
≈ $4.75 Million
-62.38%
2017-12-31 ₩18.64 Billion
≈ $12.63 Million
-7.41%
2016-12-31 ₩20.13 Billion
≈ $13.64 Million
+40.99%
2015-12-31 ₩14.28 Billion
≈ $9.68 Million
+84.03%
2014-12-31 ₩7.76 Billion
≈ $5.26 Million
-63.45%
2013-12-31 ₩21.23 Billion
≈ $14.38 Million
-1.09%
2012-12-31 ₩21.46 Billion
≈ $14.54 Million
+2.68%
2011-12-31 ₩20.90 Billion
≈ $14.16 Million
+193.93%
2007-12-31 ₩7.11 Billion
≈ $4.82 Million
--

About NanoenTekInc

KQ:039860 Korea Scientific & Technical Instruments
Market Cap
$95.53 Million
₩140.96 Billion KRW
Market Cap Rank
#19447 Global
#981 in Korea
Share Price
₩4390.00
Change (1 day)
-1.79%
52-Week Range
₩3030.00 - ₩7670.00
All Time High
₩14900.00
About

NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a resid… Read more